SCOTTSDALE, Ariz., May 26, 2010 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced 91.2% of patients who made a selection in the Dysport Challenge promoting Dysport (abobotulinumtoxinA) 300 Units for Injection chose “Love It."(1) Since its introduction on March 1, tens of thousands of patients have participated in the Dysport Challenge,(1) and patients continue to register daily. The Company recently announced an extension of its popular offer through May 31, 2010, and is now extending it another 120 days due to continued overwhelming response. Approved by the U.S. Food and Drug Administration (FDA) in April 2009, Dysport is a prescription injection used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.
